Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.97 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.